



---

# Global Commitment Register

January 12, 2023

---

GCR 22-091  
PROPOSED

## **Specialty Drug List Change**

### **Policy Summary:**

The Vermont Medicaid program proposes to remove certain drugs from the specialty drug list, expanding access to these drugs as this will allow dispensing at any enrolled pharmacy. This proposal will change the coding on these drugs resulting in reduced dispensing fees and expanded access.

The specialty drug list includes drugs associated with high costs, complicated prescribing and monitoring requirements, and complex disease state management. These drugs must be dispensed by specialty pharmacies that have nationally recognized specialty certification.

Requirements for inclusion on the specialty drug list must include two (2) of the following:

- The cost of the medication exceeds \$5,000 per month.
- The medication is used in the treatment of a complex, chronic condition. This may include, but is not limited to, drugs that require administration, infusion, or injection by a health care professional.
- The manufacturer or FDA requires exclusive, restricted, or limited distribution. This includes medications that have REMS requirements for training, certifications, or ongoing monitoring for the drug to be distributed.
- The medication requires specialized handling, storage, or inventory reporting requirements.

The following medications no longer meet the criteria for inclusion on the specialty drug list:

- **Praluent®** (alirocumab), **Repatha®** (evolocumab), **Humira®** (adalimumab), **Enbrel®** (etanercept), **Veltassa®** (patiromer calcium sorbitex), **Jatenzo®** (testosterone undecanoate), and **Tlando®** (testosterone undecanoate)

The DVHA Pharmacy Unit will periodically review the specialty drug list for Vermont Medicaid. Any further alterations to the specialty drug list will be accompanied by appropriate provider notice prior to the change taking effect.

### **Effective Date:**

January 13, 2023

**Authority/Legal Basis:**

[Medicaid State Plan](#)

**Population Affected:**

All Medicaid

**Fiscal Impact:**

The estimated gross annualized budget impact is a savings of \$19,900.

**Public Comment Period:**

January 12, 2023 – February 13, 2023

Send comments to:

Medicaid Policy Unit

280 State Drive, Center Building

Waterbury, VT 05671-1000

Or submit via e-mail to [AHS.MedicaidPolicy@vermont.gov](mailto:AHS.MedicaidPolicy@vermont.gov).

To be added to the GCR email list, send an email to [AHS.MedicaidPolicy@vermont.gov](mailto:AHS.MedicaidPolicy@vermont.gov).

**Additional Information:**

The specialty drug list is located here: [Drug Coverage Lists | Department of Vermont Health Access](#)